About Auspex Pharmaceuticals (NASDAQ:ASPX)
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E Ratio-36.8467153284671
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-61.66%
Return on Assets-50.55%
Auspex Pharmaceuticals (NASDAQ:ASPX) Frequently Asked Questions
What is Auspex Pharmaceuticals' stock symbol?
Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."
How were Auspex Pharmaceuticals' earnings last quarter?
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) issued its quarterly earnings data on Monday, March, 16th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.
Who are some of Auspex Pharmaceuticals' key competitors?
Some companies that are related to Auspex Pharmaceuticals include Shire-Nps Pharmaceuticals (NPSP), Beigene (BGNE), Sarepta Therapeutics (SRPT), TESARO (TSRO), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH), AveXis (AVXS), Halozyme Therapeutics (HALO), Clovis Oncology (CLVS), Loxo Oncology (LOXO), China Biologic Products (CBPO), Array BioPharma (ARRY), AnaptysBio (ANAB), Insmed (INSM), Aerie Pharmaceuticals (AERI), Acceleron Pharma (XLRN), Ultragenyx Pharmaceutical (RARE) and Spark Therapeutics (ONCE).
How do I buy Auspex Pharmaceuticals stock?
Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auspex Pharmaceuticals' stock price today?
One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $100.96.
How big of a company is Auspex Pharmaceuticals?
Auspex Pharmaceuticals has a market capitalization of $3.21 billion.
How can I contact Auspex Pharmaceuticals?
Auspex Pharmaceuticals' mailing address is 3333 N Torrey Pines Ct Ste 400, LA JOLLA, CA 92037-1023, United States. The biopharmaceutical company can be reached via phone at +1-858-5582400.
MarketBeat Community Rating for Auspex Pharmaceuticals (ASPX)MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Auspex Pharmaceuticals (NASDAQ:ASPX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Auspex Pharmaceuticals (NASDAQ:ASPX) Earnings History and Estimates Chart
Auspex Pharmaceuticals (NASDAQ ASPX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Auspex Pharmaceuticals (NASDAQ:ASPX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by MarketBeat.com
Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trading and Institutional Ownership History
Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/16/2015||David A Stamler||Insider||Sell||3,000||$80.00||$240,000.00|| |
|2/13/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||122,667||$63.08||$7,737,834.36|| |
|2/11/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||84,154||$61.06||$5,138,443.24|| |
|2/6/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||93,179||$59.39||$5,533,900.81|| |
|1/28/2015||Alex Zisson||Director||Sell||730,000||$53.11||$38,770,300.00|| |
|1/28/2015||James E Flynn||Insider||Buy||1,500,000||$56.50||$84,750,000.00|| |
|1/28/2015||Panorama Capital, L.P.||Major Shareholder||Sell||270,000||$53.11||$14,339,700.00|| |
|12/22/2014||David A Stamler||Insider||Sell||2,660||$53.55||$142,443.00|| |
|12/18/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||195,000||$50.14||$9,777,300.00|| |
|10/30/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||19,000||$27.15||$515,850.00|| |
|10/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||14,500||$27.02||$391,790.00|| |
|10/27/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||3,413||$27.11||$92,526.43|| |
|10/24/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||16,500||$26.97||$445,005.00|| |
|10/6/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||7,109||$23.45||$166,706.05|| |
|9/19/2014||Gerald T Proehl||Director||Buy||1,466||$21.75||$31,885.50|| |
|9/5/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||25,600||$23.86||$610,816.00|| |
|9/3/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||22,700||$23.08||$523,916.00|| |
|8/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||29,600||$22.03||$652,088.00|| |
|8/26/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||6,300||$21.35||$134,505.00|| |
|8/22/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||1,700||$20.56||$34,952.00|| |
|7/16/2014||R Scott Greer||Director||Buy||5,190||$19.25||$99,907.50|| |
|2/10/2014||James E Flynn||Insider||Buy||700,000||$12.00||$8,400,000.00|| |
|2/10/2014||Panorama Capital, L.P.||Major Shareholder||Buy||333,334||$12.00||$4,000,008.00|| |
|2/10/2014||Pratik Shah||CEO||Buy||8,333||$12.00||$99,996.00|| |
|2/10/2014||Sepehr Sarshar||Director||Buy||67,263||$12.00||$807,156.00|| |
Auspex Pharmaceuticals (NASDAQ ASPX) News Headlines
Auspex Pharmaceuticals (NASDAQ:ASPX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Auspex Pharmaceuticals (NASDAQ:ASPX) Income Statement, Balance Sheet and Cash Flow Statement
Auspex Pharmaceuticals (NASDAQ ASPX) Stock Chart for Thursday, January, 18, 2018